Greylin Investment Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $9.48M | Buy |
338,910
+89,238
| +36% | +$2.46M | 1.59% | 11 |
|
|
2024
Q1 | $6.93M | Buy |
249,672
+76,137
| +44% | +$2.11M | 1.11% | 17 |
|
|
2023
Q4 | $5M | Buy |
173,535
+155,355
| +855% | +$4.7M | 0.86% | 22 |
|
|
2023
Q3 | $603K | Sell |
18,180
-1,653
| -8% | -$58.5K | 0.11% | 51 |
|
|
2023
Q2 | $727K | Sell |
19,833
-2,630
| -12% | -$102K | 0.13% | 48 |
|
|
2023
Q1 | $916K | Sell |
22,463
-3,171
| -12% | -$137K | 0.17% | 44 |
|
|
2022
Q4 | $1.31M | Sell |
25,634
-5,943
| -19% | -$285K | 0.24% | 37 |
|
|
2022
Q3 | $1.38M | Sell |
31,577
-16,465
| -34% | -$800K | 0.29% | 35 |
|
|
2022
Q2 | $2.52M | Sell |
48,042
-112,950
| -70% | -$5.76M | 0.49% | 32 |
|
|
2022
Q1 | $8.34M | Sell |
160,992
-17,334
| -10% | -$899K | 1.43% | 17 |
|
|
2021
Q4 | $10.5M | Sell |
178,326
-3,223
| -2% | -$160K | 1.98% | 10 |
|
|
2021
Q3 | $7.81M | Sell |
181,549
-650
| -0.4% | -$28.8K | 1.6% | 12 |
|
|
2021
Q2 | $7.13M | Buy |
182,199
+2,445
| +1% | +$95.1K | 1.38% | 14 |
|
|
2021
Q1 | $6.51M | Buy |
179,754
+6,526
| +4% | +$232K | 1.36% | 15 |
|
|
2020
Q4 | $6.38M | Sell |
173,228
-9,439
| -5% | -$346K | 1.49% | 13 |
|
|
2020
Q3 | $6.36M | Buy |
182,667
+16,061
| +10% | +$563K | 1.7% | 11 |
|
|
2020
Q2 | $5.17M | Buy |
166,606
+114,313
| +219% | +$3.88M | 1.46% | 16 |
|
|
2020
Q1 | $1.62M | Buy |
52,293
+1,366
| +3% | +$46.5K | 0.5% | 29 |
|
|
2019
Q4 | $1.89M | Buy |
50,927
+667
| +1% | +$23.8K | 0.42% | 33 |
|
|
2019
Q3 | $1.71M | Buy |
50,260
+632
| +1% | +$23K | 0.41% | 33 |
|
|
2019
Q2 | $2.04M | Sell |
49,628
-3,399
| -6% | -$135K | 0.46% | 31 |
|
|
2019
Q1 | $2.14M | Sell |
53,027
-3,979
| -7% | -$159K | 0.48% | 34 |
|
|
2018
Q4 | $2.36M | Sell |
57,006
-2,081
| -4% | -$86.4K | 0.57% | 29 |
|
|
2018
Q3 | $2.47M | Sell |
59,087
-2,662
| -4% | -$102K | 0.53% | 32 |
|
|
2018
Q2 | $2.13M | Buy |
61,749
+507
| +0.8% | +$17.3K | 0.46% | 36 |
|
|
2018
Q1 | $2.06M | Sell |
61,242
-299
| -0.5% | -$10.3K | 0.45% | 32 |
|
|
2017
Q4 | $2.12M | Buy |
61,541
+1,518
| +3% | +$51.8K | 0.46% | 32 |
|
|
2017
Q3 | $2.03M | Sell |
60,023
-843
| -1% | -$27.1K | 0.47% | 31 |
|
|
2017
Q2 | $1.94M | Buy |
60,866
+4,133
| +7% | +$130K | 0.45% | 29 |
|
|
2017
Q1 | $1.84M | Buy |
56,733
+8,485
| +18% | +$268K | 0.43% | 28 |
|
|
2016
Q4 | $1.49M | Buy |
48,248
+13,175
| +38% | +$402K | 0.36% | 32 |
|
|
2016
Q3 | $1.13M | Buy |
35,073
+264
| +0.8% | +$8.83K | 0.28% | 38 |
|
|
2016
Q2 | $1.16M | Buy |
34,809
+2,345
| +7% | +$74.8K | 0.29% | 35 |
|
|
2016
Q1 | $913K | Sell |
32,464
-1,002
| -3% | -$28.6K | 0.24% | 36 |
|
|
2015
Q4 | $1.02M | Sell |
33,466
-1,317
| -4% | -$41.4K | 0.28% | 33 |
|
|
2015
Q3 | $1.04M | Sell |
34,783
-1,686
| -5% | -$54.1K | 0.29% | 28 |
|
|
2015
Q2 | $1.16M | Buy |
36,469
+1,212
| +3% | +$39.5K | 0.29% | 29 |
|
|
2015
Q1 | $1.04M | Buy |
35,257
+105
| +0.3% | +$3.34K | 0.25% | 32 |
|
|
2014
Q4 | $1.04M | Buy |
35,152
+1,159
| +3% | +$33.2K | 0.25% | 32 |
|
|
2014
Q3 | $954K | Sell |
33,993
-141
| -0.4% | -$3.96K | 0.23% | 31 |
|
|
2014
Q2 | $961K | Buy |
34,134
+15,586
| +84% | +$444K | 0.23% | 31 |
|
|
2014
Q1 | $565K | Buy |
18,548
+1,497
| +9% | +$44.6K | 0.14% | 49 |
|
|
2013
Q4 | $496K | Buy |
17,051
+527
| +3% | +$15.3K | 0.12% | 51 |
|
|
2013
Q3 | $450K | Sell |
16,524
-1,921
| -10% | -$52.3K | 0.23% | 27 |
|
|
2013
Q2 | $490K | Buy |
+18,445
| New | +$510K | 0.16% | 29 |
|
Other funds holding PFE
Greylin Investment Management's PFE Position: Q2 2024 in Review
Greylin Investment Management increased its Pfizer (PFE) stake by 36% in Q2 2024, buying an estimated $2.46M and bringing the position to 338,910 shares worth $9.48M. The position accounts for 1.59% of the portfolio, ranked #11.
Greylin Investment Management first reported a position in PFE in Q2 2013 and has held it in 45 quarters since. The position peaked at $10.5M in Q4 2021. 2,874 funds tracked by Wall St. Rank hold PFE as of Q2 2024.
- Greylin Investment Management held 338,910 shares of Pfizer worth $9.48M as of Q2 2024.
- Greylin Investment Management bought 89,238 Pfizer shares in Q2 2024, an estimated $2.46M.
- Pfizer made up 1.59% of Greylin Investment Management's portfolio in Q2 2024, its #11 holding.
- Greylin Investment Management first reported a position in Pfizer in Q2 2013 and has held it in 45 quarters since.
- Greylin Investment Management's Pfizer position peaked at $10.5M in Q4 2021.
- 2,874 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.
Based on Greylin Investment Management's 13F filing for Q2 2024, filed 19 Jul 2024.